{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:50:12Z","timestamp":1769176212221,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.neulet.2019.02.014","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T17:09:23Z","timestamp":1549818563000},"page":"184-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Simple surface EMG recording as a noninvasive screening method for the detection of acute oxaliplatin-induced neurotoxicity: a feasibility pilot study"],"prefix":"10.1016","volume":"699","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8292-1692","authenticated-orcid":false,"given":"Sandra A.S. van den","family":"Heuvel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonne","family":"Doorduin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique A.H.","family":"Steegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewald M","family":"Bronkhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra A","family":"Radema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris C.P.","family":"Vissers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina E.I. van der","family":"Wal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nens van","family":"Alfen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2019.02.014_bib0005","first-page":"1765","article-title":"Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting","volume":"33","author":"Moreau","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neulet.2019.02.014_bib0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ijc.25369","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer","volume":"128","author":"Ducreux","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.neulet.2019.02.014_bib0015","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0020","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.neulet.2019.02.014_bib0025","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: a comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"Suppl 4","key":"10.1016\/j.neulet.2019.02.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neulet.2019.02.014_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COC.0b013e318246b50d","article-title":"Predicting acute and persistent neuropathy associated with oxaliplatin","volume":"36","author":"Alejandro","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00280-007-0454-3","article-title":"Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin","volume":"61","author":"Petrioli","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0045","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2006.08.6652","article-title":"Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07","volume":"25","author":"Land","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","article-title":"Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer","volume":"5","author":"Leonard","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neulet.2019.02.014_bib0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1345\/aph.1E319","article-title":"Oxaliplatin-associated neuropathy: a review","volume":"39","author":"Cersosimo","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neulet.2019.02.014_bib0060","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0065","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/843019","article-title":"Neurotoxicity caused by the treatment with platinum analogues","author":"Amptoulach","year":"2011","journal-title":"Chemother. Res. Pract."},{"key":"10.1016\/j.neulet.2019.02.014_bib0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/sonc.2002.35524","article-title":"Oxaliplatin-related side effects: characteristics and management","volume":"29","author":"Cassidy","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mus.10559","article-title":"Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy","volume":"29","author":"Lehky","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neulet.2019.02.014_bib0080","article-title":"Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity","volume":"6","author":"Park","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2019.02.014_bib0085","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1073\/pnas.1118058109","article-title":"Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current","volume":"109","author":"Sittl","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2019.02.014_bib0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","article-title":"The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons","volume":"406","author":"Adelsberger","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0095","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.clinph.2017.11.015","article-title":"Axonal excitability changes and acute symptoms of oxaliplatin treatment: in vivo evidence for slowed sodium channel inactivation","volume":"129","author":"Heide","year":"2018","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0100","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","article-title":"Acute oxaliplatin-induced peripheral nerve hyperexcitability","volume":"20","author":"Wilson","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1874467210801010061","article-title":"Pharmacologic intervention in axonal excitability: in vivo assessment of nodal persistent sodium currents in human neuropathies","volume":"1","author":"Kuwabara","year":"2008","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0110","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy","volume":"132","author":"Park","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neulet.2019.02.014_bib0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mus.20340","article-title":"Oxaliplatin-induced neurotoxicity and the development of neuropathy","volume":"32","author":"Krishnan","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neulet.2019.02.014_bib0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mus.20849","article-title":"Interspike interval analysis in a patient with peripheral nerve hyperexcitability and potassium channel antibodies","volume":"37","author":"Kleine","year":"2008","journal-title":"Muscle Nerve"},{"issue":"Pt 2","key":"10.1016\/j.neulet.2019.02.014_bib0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/brain\/116.2.453","article-title":"Immunological associations of acquired neuromyotonia (Isaacs\u2019 syndrome). Report of five cases and literature review","volume":"116","author":"Newsom-Davis","year":"1993","journal-title":"Brain"},{"key":"10.1016\/j.neulet.2019.02.014_bib0130","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.20536","article-title":"Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability","volume":"33","author":"Maddison","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neulet.2019.02.014_bib0135","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awf178","article-title":"Phenotypic variants of autoimmune peripheral nerve hyperexcitability","volume":"125","author":"Hart","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neulet.2019.02.014_bib0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1254\/jphs.10012SC","article-title":"Mexiletine reverses oxaliplatin-induced neuropathic pain in rats","volume":"112","author":"Egashira","year":"2010","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neulet.2019.02.014_bib0145","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuropharm.2008.06.007","article-title":"Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection","volume":"55","author":"Ling","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2019.02.014_bib0150","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jpainsymman.2007.01.016","article-title":"Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients","volume":"34","author":"Locke","year":"2007","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.neulet.2019.02.014_bib0155","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.4081\/ni.2014.5208","article-title":"Another Perspective on Fasciculations: When is it not Caused by the Classic form of Amyotrophic Lateral Sclerosis or Progressive Spinal Atrophy?","volume":"6","author":"Leite","year":"2014","journal-title":"Neurol. Int."},{"key":"10.1016\/j.neulet.2019.02.014_bib0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12883-015-0294-4","article-title":"Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol","volume":"15","author":"Stunnenberg","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neulet.2019.02.014_bib0165","series-title":"Electromyography and Neuromuscular Disorders: Clinical-electrophysiological Correlations","first-page":"pp 220","article-title":"Chapter 14 basic electromyography: analysis of spontaneous activity","author":"Preston","year":"2013"},{"key":"10.1016\/j.neulet.2019.02.014_bib0170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/1471-2407-10-451","article-title":"Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability","volume":"10","author":"Hill","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neulet.2019.02.014_bib0175","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2013-305334","article-title":"Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients","volume":"85","author":"Velasco","year":"2014","journal-title":"J Neurol. Neurosurg. Psychiatry"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394019300977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394019300977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:27:09Z","timestamp":1759609629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394019300977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":35,"alternative-id":["S0304394019300977"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2019.02.014","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simple surface EMG recording as a noninvasive screening method for the detection of acute oxaliplatin-induced neurotoxicity: a feasibility pilot study","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2019.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}